Abstract: A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.
Type:
Grant
Filed:
May 10, 2006
Date of Patent:
October 30, 2012
Assignee:
Novartis AG
Inventors:
Glenn C. Michelson, Vivien W. Chan, Carla C. Heise, Marion Wiesmann, Timothy D. Dawes
Abstract: Physically and chemically stable, oxidation-resistant, cosmetic/dermatological inverse emulsions contain a therapeutically effective amount of at least one avermectin compound, notably ivermectin, a glycolic or aqueous/glycolic dispersed hydrophilic phase, a continuous lipophilic phase and an emulsifier having an HLB ranging from 2 and 7, and are useful for the treatment of a variety of dermatological conditions/afflictions, e.g., rosacea.
Abstract: The invention provides for the use of isovaline or a pharmaceutically acceptable salt thereof for the treatment of Pain in a mammalian subject in some preferred embodiments, the invention provides for the treatment of acute and chronic Pain syndromes where other drug therapies have limited efficacy or unacceptable toxicity in said subject.
Type:
Grant
Filed:
September 12, 2007
Date of Patent:
October 2, 2012
Assignee:
Therexcell Pharma Inc.
Inventors:
Ernest Puil, Bernard Ansel MacLeod, Thomas Michael Stokes, Wei Liu
Abstract: The present invention relates to articles to be worn in contact with a mammal body, such as sanitary napkins, pantiliners, nursing pads, baby diapers and the like. The article includes a mint odor-free cooling agent able to convey freshness sensation to the wearer of the article, without the need of modifying body surface temperature.
Type:
Grant
Filed:
October 17, 2003
Date of Patent:
September 25, 2012
Assignee:
The Procter and Gamble Company
Inventors:
Antonella Pesce, Daniela Meo, Giovanni Carlucci, Achille Di Cintio
Abstract: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
Abstract: The invention relates to a method of administering histamine H3 antagonist and an antipsychotic therapeutic agent, compositions comprising a histamine H3 antagonist and an antipsychotic therapeutic agent, and a related article of manufacture.
Type:
Grant
Filed:
June 3, 2010
Date of Patent:
August 28, 2012
Assignee:
Abbott Laboratories
Inventors:
Lynne E. Rueter, Kaitlin E. Browman, Jorge D. Brioni, Marlon D. Cowart, Timothy A. Esbenshade, Gerard B. Fox
Abstract: Described herein are synthetically modified fullerene molecules, wherein the fullerene is preferably ellipsoid in shape with an equatorial band and two opposing poles, comprising an adduct at one or both poles, at least one adduct being a hydrophobic chemical moiety capable of anchoring the fullerene on or in a lipid membrane.
Type:
Grant
Filed:
March 3, 2008
Date of Patent:
August 14, 2012
Assignee:
Luna Innovations Incorporated
Inventors:
Zhiguo Zhou, Robert P. Lenk, Darren Macfarland, Kenneth L. Walker, Jing Zhang, Stephen R. Wilson
Abstract: Ascorbic acid compositions in the form of a powder and/or granules contain as principle components L-ascorbic acid and/or a pharmaceutically acceptable salt thereof, and a high molecular (300 kDalton or higher) pectin. The compositions are compressible into tablets with improved mechanical strength and hardness.
Abstract: A method for treating the symptoms of multiple sclerosis and related neurodegenerative conditions, using a histamine compound that is methylated in vitro prior to being introduced into the body of the patient. The histamine compound is suitably histamine diphosphate, and may be methylated in vitro by mixing in combination with at least one thiol compound in the presence of at least one methyl group donor compound. The thiol compound is suitably L-reduced glutathione and the methyl group donor is suitably betaine hydrochloride. The compounds are mixed vigorous in an acid environment, to create a shearing force that facilitates exchange of the methyl group from the donor compound to the histamine diphosphate. The resulting methylated histamine compound is suitably administered to the patient by transdermal application. The method also provides a medicament for treatment the symptoms of multiple sclerosis and related neurodegenerative conditions, and a method for preparation of such a medicament.
Abstract: The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.
Type:
Grant
Filed:
April 10, 2007
Date of Patent:
June 19, 2012
Assignee:
Fondazione IRCCS “CA' Granda—Ospedale Maggiore Policlinico”
Abstract: The present invention relates to pharmaceutical compositions for intranasal administration to a mammal that contain an effective amount of an opioid, a liquid nasal carrier for the opioid, and optionally a sweetener, flavoring agent or masking agent. In some embodiments of the present invention, the pharmaceutical compositions have improved bioavailability. In other embodiments of the present invention, the opioid compositions improve patient compliance.
Type:
Grant
Filed:
April 7, 2010
Date of Patent:
June 12, 2012
Assignee:
University of Kentucky Research Foundation
Abstract: Compositions and methods for treating chronic infectious diseases using substantially pure oxymatrine or pharmaceutically acceptable salts or esters thereof are disclosed. In one embodiment described herein, the chronic infectious disease is chronic fatigue syndrome. Further described are compositions having an anti-infective amount of substantially pure oxymatrine or pharmaceutically acceptable salts or esters thereof.
Abstract: There is Provided an Agent for Prevention of glaucoma or an agent for prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. An agent for prevention or treatment of glaucoma comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination.
Abstract: The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries.
Abstract: Disclosed is a microorganism control agent containing not less than 1% by weight but less than 10% by weight of N,N?-hexamethylenebis(4-carbamoyl-1-decylpyridinium bromide), not less than 35% by weight but less than 60% by weight of at least one alcohol having 2 or 3 carbon atoms, water and an acid.
Abstract: Compounds and compositions for treating disorders related to TRPA1 are described herein.
Type:
Grant
Filed:
June 23, 2008
Date of Patent:
April 24, 2012
Assignee:
Hydra Biosciences, Inc.
Inventors:
Howard Ng, Manfred Weigele, Magdalene Moran, Jayhong Chong, Christopher Fanger, Glenn R. Larsen, Donato Del Camino, Neil Hayward, Steven P. Adams, Amy Ripka
Abstract: The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
Type:
Grant
Filed:
April 27, 2007
Date of Patent:
April 17, 2012
Assignee:
Northwestern University
Inventors:
D. Martin Watterson, Linda Van Eldik, Wenhui Hu
Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.
Type:
Grant
Filed:
November 27, 2006
Date of Patent:
April 3, 2012
Assignee:
Senju Pharmaceutical Co., Ltd.
Inventors:
Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
Abstract: The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart.
Type:
Grant
Filed:
February 13, 2004
Date of Patent:
March 13, 2012
Assignee:
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center
Inventors:
Nestor F. Gonzalez-Cadavid, Jacob Rajfer